论文部分内容阅读
Long-term administration of L-3,4-dihydroxyphenilalanine (levodopa),the mainstay treatment for Parkinson s disease (PD),is accompanied by fluctuations in its duration of action and disabling motor complications termed dyskinesias.To date,no effective anti-dyskinetic treatments are available and there is a strong need for new pharmacological strategies.